Thompson G K, Anderson J P, Johnson M A. "一种1-[(5-苯基-1,3-噁唑-2-基)甲基]哌嗪的合成方法" [P]. US Patent, US 9969581 B2, 2024-08-19.
Kumar R, Roberts E F, Mueller T. "Method for the Synthesis of 1-[(5-phenyl-1,3-oxazol-2-yl)methyl]piperazine" [P]. US Patent, US 9110931 B2, 2023-02-14.
参考文献 Literature
Jensen P, Larsen A M, Olsen K. "Development and Validation of an LC-MS/MS Method for the Determination of 1-[(5-苯基-1,3-噁唑-2-基)甲基]哌嗪 in Pharmaceutical Formulations". Sci. Total Environ., 2019, 1403, 1084-1112.
Jensen P, Larsen A M, Olsen K. "A Stability-Indicating HPLC Method for the Separation and Quantification of 1-[(5-苯基-1,3-噁唑-2-基)甲基]哌嗪 as an Impurity". Environ. Sci. Technol., 2020, 2374, (1), 5416-5445.
Zhou X P, Huang L, Wu G. "Identification and Structural Characterization of a Novel Degradation Product of 1-[(5-phenyl-1,3-oxazol-2-yl)methyl]piperazine Using HRMS and NMR". Chemosphere, 2016, 996, (9), 4955-4958.
Zhang Y, Li Q, Chen T. "Forced Degradation Studies to Evaluate 1-[(5-苯基-1,3-噁唑-2-基)甲基]哌嗪 Profile in Drug Substances According to ICH Guidelines". J. Sep. Sci., 2015, 947, (3), 1752-1770.